Crystal L. Mackall

25.7k total citations · 12 hit papers
154 papers, 12.9k citations indexed

About

Crystal L. Mackall is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Crystal L. Mackall has authored 154 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 60 papers in Immunology and 24 papers in Molecular Biology. Recurrent topics in Crystal L. Mackall's work include CAR-T cell therapy research (111 papers), Immune Cell Function and Interaction (38 papers) and Immunotherapy and Immune Responses (24 papers). Crystal L. Mackall is often cited by papers focused on CAR-T cell therapy research (111 papers), Immune Cell Function and Interaction (38 papers) and Immunotherapy and Immune Responses (24 papers). Crystal L. Mackall collaborates with scholars based in United States, Canada and India. Crystal L. Mackall's co-authors include Robbie G. Majzner, Terry J. Fry, Rimas J. Orentas, Yongzhi Cui, Rosandra N. Kaplan, Jillian Smith, Evan W. Weber, Cindy Delbrook, Nirali N. Shah and James N. Kochenderfer and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Crystal L. Mackall

142 papers receiving 12.7k citations

Hit Papers

T cells expressing CD19 c... 2014 2026 2018 2022 2014 2015 2018 2014 2019 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
    2014 2.2k citations Daniel W Lee, James N. Kochenderfer et al. profile →
  2. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
    2015 1.3k citations Adrienne H. Long, Meera Murgai et al. profile →
  3. Tumor Antigen Escape from CAR T-cell Therapy
    2018 741 citations Robbie G. Majzner, Crystal L. Mackall Cancer Discovery profile →
  4. Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
    2014 595 citations Steven L. Highfill, Yongzhi Cui et al. profile →
  5. c-Jun overexpression in CAR T cells induces exhaustion resistance
    2019 514 citations Rachel C. Lynn, Evan W. Weber et al. profile →
  6. Tuning the Antigen Density Requirement for CAR T-cell Activity
    2020 319 citations Robbie G. Majzner, Skyler P. Rietberg et al. Cancer Discovery profile →
  7. The Emerging Landscape of Immune Cell Therapies
    2020 294 citations Evan W. Weber, Crystal L. Mackall et al. Cell profile →
  8. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence
    2022 201 citations Katherine A. Freitas, Crystal L. Mackall et al. profile →
  9. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
    2021 200 citations Nirali N. Shah, Daniel W. Lee et al. Journal of Clinical Oncology profile →
  10. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors
    2022 166 citations Louai Labanieh, Dorota D. Klysz et al. profile →
  11. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
    2024 93 citations Saurabh Dahiya, Bita Sahaf et al. profile →
  12. A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
    2024 67 citations Victor Tieu, Elena Sotillo et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Crystal L. Mackall United States 50 9.7k 4.9k 3.6k 2.8k 2.5k 154 12.9k
Cameron J. Turtle United States 48 8.7k 0.9× 3.8k 0.8× 3.0k 0.8× 2.3k 0.8× 2.4k 1.0× 167 11.8k
Michael C. Milone United States 46 11.5k 1.2× 5.8k 1.2× 4.5k 1.3× 3.6k 1.3× 3.5k 1.4× 136 15.6k
Simon F. Lacey United States 50 11.9k 1.2× 4.5k 0.9× 3.9k 1.1× 3.3k 1.2× 3.6k 1.4× 157 15.0k
J. Joseph Melenhorst United States 38 11.1k 1.1× 4.0k 0.8× 3.5k 1.0× 3.2k 1.1× 3.1k 1.2× 122 12.7k
Michael Kalos United States 39 11.7k 1.2× 6.0k 1.2× 4.9k 1.4× 2.8k 1.0× 4.1k 1.6× 97 15.5k
Sattva S. Neelapu United States 50 8.8k 0.9× 4.3k 0.9× 3.3k 0.9× 1.5k 0.5× 1.5k 0.6× 418 13.4k
Stephen Gottschalk United States 64 9.4k 1.0× 4.7k 1.0× 3.0k 0.8× 2.1k 0.8× 3.1k 1.2× 256 12.2k
Steven A. Feldman United States 36 9.6k 1.0× 4.7k 1.0× 3.1k 0.9× 2.3k 0.8× 3.0k 1.2× 87 11.4k
Terry J. Fry United States 49 8.5k 0.9× 6.2k 1.3× 2.8k 0.8× 2.1k 0.8× 2.5k 1.0× 193 13.1k
Anne Chew United States 19 8.4k 0.9× 3.3k 0.7× 2.5k 0.7× 2.3k 0.8× 2.6k 1.0× 34 9.6k

Countries citing papers authored by Crystal L. Mackall

Since Specialization
Citations

This map shows the geographic impact of Crystal L. Mackall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Crystal L. Mackall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Crystal L. Mackall more than expected).

Fields of papers citing papers by Crystal L. Mackall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Crystal L. Mackall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Crystal L. Mackall. The network helps show where Crystal L. Mackall may publish in the future.

Co-authorship network of co-authors of Crystal L. Mackall

This figure shows the co-authorship network connecting the top 25 collaborators of Crystal L. Mackall. A scholar is included among the top collaborators of Crystal L. Mackall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Crystal L. Mackall. Crystal L. Mackall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
DeSantes, Kenneth B., Kimberly A. McDowell, Paul M. Sondel, et al.. (2025). A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors. Cancer Research Communications. 5(9). 1574–1583. 1 indexed citations
3.
Srinagesh, Hrishikesh K., Anne Marijn Kramer, John H. Baird, et al.. (2025). Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome. Blood Cancer Discovery. 7(2). 225–233.
4.
Tieu, Victor, Elena Sotillo, Meena Malipatlolla, et al.. (2024). A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell. 187(5). 1278–1295.e20. 67 indexed citations breakdown →
5.
Kaczanowska, Sabina, Donna Bernstein, Nan Zhang, et al.. (2023). 621 A phase I study of autologous activated NK cells ± rhIL15 in children and young adults with refractory solid tumors. SHILAP Revista de lepidopterología. A708–A708. 1 indexed citations
6.
Davis, Kara L., Elizabeth Fox, Joel M. Reid, et al.. (2022). A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. Clinical Cancer Research. 28(23). 5088–5097. 43 indexed citations
7.
Molina, John C., Ting Zhou, Constance M. Yuan, et al.. (2022). Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. Journal for ImmunoTherapy of Cancer. 10(5). e004483–e004483. 31 indexed citations
8.
Richards, Rebecca M., Feifei Zhao, Katherine A. Freitas, et al.. (2021). NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. Blood Cancer Discovery. 2(6). 648–665. 65 indexed citations
9.
Simonetta, Federico, Juliane K. Lohmeyer, Toshihito Hirai, et al.. (2021). Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. Clinical Cancer Research. 27(21). 6054–6064. 44 indexed citations
10.
Molina, John C., Seth M. Steinberg, Bonnie Yates, et al.. (2021). Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 28(1). 31.e1–31.e9. 12 indexed citations
11.
Frank, Matthew J., Nasheed Hossain, Ali Bukhari, et al.. (2021). Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. Journal of Clinical Oncology. 39(27). 3034–3043. 87 indexed citations
12.
Majzner, Robbie G., Skyler P. Rietberg, Elena Sotillo, et al.. (2020). Tuning the Antigen Density Requirement for CAR T-cell Activity. Cancer Discovery. 10(5). 702–723. 319 indexed citations breakdown →
13.
Murty, Surya, Louai Labanieh, Tara Murty, et al.. (2020). PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Research. 80(21). 4731–4740. 28 indexed citations
14.
Su, Yichi, Joel R. Walker, Yun‐Hee Park, et al.. (2020). Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals. Nature Methods. 17(8). 852–860. 128 indexed citations
15.
Giles, Amber, Caitlin Marie Reid, Meera Murgai, et al.. (2016). Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre–metastatic Niche. Cancer Research. 76(6). 1335–1347. 117 indexed citations
16.
Long, Adrienne H., Steven L. Highfill, Yongzhi Cui, et al.. (2016). Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. Cancer Immunology Research. 4(10). 869–880. 258 indexed citations
17.
Vo, Kieuhoa T., C. Lorrie Epling, Elizabeth Sinclair, et al.. (2016). Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research. 22(14). 3643–3650. 17 indexed citations
18.
19.
Merchant, Melinda S., Matthew Wright, Kristin Baird, et al.. (2015). Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(6). 1364–1370. 234 indexed citations
20.
Merchant, Melinda S., et al.. (2006). Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunology Immunotherapy. 56(7). 1037–1046. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cameron J. Turtle Breakdown of academic impact, for papers by Michael C. Milone Breakdown of academic impact, for papers by Simon F. Lacey Breakdown of academic impact, for papers by J. Joseph Melenhorst Breakdown of academic impact, for papers by Michael Kalos Breakdown of academic impact, for papers by Sattva S. Neelapu Breakdown of academic impact, for papers by Stephen Gottschalk Breakdown of academic impact, for papers by Steven A. Feldman Breakdown of academic impact, for papers by Terry J. Fry Breakdown of academic impact, for papers by Anne Chew
Rankless by CCL
2026